Delivery Order SPE2DB22D3301-SPE2DB26FX4EL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this delivery order represents one...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $10,662.57 and a firm fixed price structure. This delivery order, issued under a competitive, non-set-aside procurement, is scheduled for completion by October 16, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of Tagrisso 40 mg tablets (30-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy used in treating certain lung cancers,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Tagrisso 80 mg tablets (quantity: 30-count packages) with a ceiling value of $21,303.64. This firm fixed-price delivery order, which is not set-aside designated, is scheduled for completion by September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, consistent...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX4ELDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages) under a firm fixed-price contract valued at $10,662.57. This non-set-aside award, issued on October 31, 2025, is scheduled for completion by November 24, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, reflecting the DLA's ongoing pharmaceutical procurement requirements for military and federal healthcare systems. This delivery order represents a task order issued against AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies across multiple therapeutic domains to support military healthcare programs globally. The company's capacity to fulfill this specialized oncology pharmaceutical request demonstrates its role as a key provider within the federal supply chain for the Department of Defense health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 10/31/25 |